Breaking News Instant updates and real-time market news.

ENTA

Enanta

$30.82

-0.025 (-0.08%)

, ABBV

AbbVie

$63.78

0.33 (0.52%)

06:42
04/21/17
04/21
06:42
04/21/17
06:42

Enanta: Glecaprevir/pibrentasvir shows virologic response in AbbVie's HCV study

Enanta Pharmaceuticals (ENTA) reported that AbbVie (ABBV) announced high SVR rates were achieved with 8 weeks of treatment with its investigational, once daily, ribavirin-free, pan-genotypic regimen of glecaprevir/pibrentasvir in patients with challenging-to-treat genotype 3 chronic hepatitis C virus infection. In results from AbbVie's Phase 3 ENDURANCE-3 study, 95% of GT3 chronic HCV-infected patients without cirrhosis and who were new to treatment achieved sustained virologic response at 12 weeks post-treatment following 8 weeks of treatment with G/P. These results will be featured as an oral presentation at The International Liver Congress in Amsterdam. In addition to evaluating 8 weeks of treatment with G/P, the ENDURANCE-3 study was designed to evaluate whether 12 weeks of G/P treatment is non-inferior to 12 weeks of sofosbuvir plus daclatasvir, a current standard of care for GT3 chronic HCV-infected patients. SVR12 rates of 95% were seen in both 8 weeks and 12 weeks of treatment with G/P. Additionally, 12 weeks of treatment with G/P was demonstrated to be non-inferior to 12 weeks of treatment with SOF+DCV. In the ENDURANCE-3 study, no patients who received 8 weeks of G/P discontinued treatment due to adverse events. Authorization applications for G/P are currently under review by regulatory authorities around the world. G/P has been granted accelerated assessment by the European Medicines Agency, and priority review designations by the FDA and Japanese Ministry of Health, Labour and Welfare. G/P is an investigational regimen and its safety and efficacy have not been established.

ENTA

Enanta

$30.82

-0.025 (-0.08%)

ABBV

AbbVie

$63.78

0.33 (0.52%)

  • 27

    Apr

  • 03

    May

  • 08

    May

  • 06

    Jun

ENTA Enanta
$30.82

-0.025 (-0.08%)

04/28/16
JMPS
04/28/16
DOWNGRADE
JMPS
Market Perform
Enanta downgraded to Market Perform from Outperform at JMP Securities
ABBV AbbVie
$63.78

0.33 (0.52%)

04/17/17
JEFF
04/17/17
NO CHANGE
Target $97
JEFF
Buy
Jefferies sees Lilly trading down 5% on baricitinib CRL
Jefferies analyst Jeffrey Holford expects Eli Lilly (LLY) to trade down around 5% after the company and Incyte (INCY) received a complete response letter from the FDA for baricitinib. A significant delay to the U.S. approval of baricitinib could hit Lilly's mid-term earnings and valuation by up to 8%-10%, Holford tells investors in a research note. He notes, however, that the cause or extent of the delay is unclear at this point. Holford keeps a Buy rating on Lilly with a $97 price target. The analyst views the baricitinib CRL as a positive for AbbVie's (ABBV) "best in class" JAK inhibitor, ABT-4494. A delay to baricitinib could result in ABT-494 reaching the U.S. market before baricitinib, the analyst contends.
04/20/17
LEER
04/20/17
NO CHANGE
Target $71
LEER
Market Perform
AbbVie veliparib not competitive with other products, says Leerink
Leerink analyst Geoffrey Porges notes that AbbVie announced failed top-line results for its PARP inhibitor veliparib in combination with chemotherapy for metastatic squamous NSCLC and early TNBC. While two disappointing trials would not normally completely doom a program, the analyst says that the lack of effect confirms his view that veliparib has limited activity and is not competitive with other products in this class. For this reason, Porges is taking the probability of success of the program to zero. The analyst reiterated a Market Perform rating on the stock and lowered his price target on the shares to $71 from $72.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $90
JEFF
Buy
AbbVie cancer drug failure should have little impact, says Jefferies
Jefferies analyst Jeffrey Holford expects the Phase III failure of veliparib to have little impact on AbbVie shares. The analyst says expectations were low and that the drug accounted for less than 1% of his mid-term revenues estimates. He keeps a Buy rating on AbbVie with a $90 price target.
04/20/17
RHCO
04/20/17
NO CHANGE
RHCO
Tesaro has no negative read through from AbbVie failure, says SunTrust
SunTrust analyst Peter Lawson says that there is "no impact" on Tesaro's (TSRO) niraparib from the failure of AbbVie's (ABBV) PARP inhibitor, veliparib, in triple negative breast cancer and lung cancer. The analyst believes that niraparib could be more effective than veliparib. Additionally, he notes that during its trial veliparib was used in combination with chemotherapy, while niraparib will be combined with Merck's (MRK) Keytruda for its trial. He thinks that the pairing with Keytruda will result in more effective treatment. The analyst keeps a $235 price target and a Buy rating on Tesaro.

TODAY'S FREE FLY STORIES

BBBY

Bed Bath & Beyond

$27.30

-1.37 (-4.78%)

15:04
09/19/17
09/19
15:04
09/19/17
15:04
Options
Bed Bath & Beyond options imply 13.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

IO

ION Geophysical

$9.75

0.05 (0.52%)

15:03
09/19/17
09/19
15:03
09/19/17
15:03
Conference/Events
ION Geophysical management to meet with Evercore ISI »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

UNIT

Uniti Group

$17.47

-0.93 (-5.05%)

, WIN

Windstream

$2.01

-0.03 (-1.47%)

15:02
09/19/17
09/19
15:02
09/19/17
15:02
Hot Stocks
S&P downgrades Uniti Group to 'B' on downgrade of Windstream »

S&P Global Ratings…

UNIT

Uniti Group

$17.47

-0.93 (-5.05%)

WIN

Windstream

$2.01

-0.03 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

WIN

Windstream

$2.01

-0.03 (-1.47%)

, UNIT

Uniti Group

$17.47

-0.93 (-5.05%)

15:02
09/19/17
09/19
15:02
09/19/17
15:02
Recommendations
Windstream, Uniti Group analyst commentary  »

Windstream, Uniti selloff…

WIN

Windstream

$2.01

-0.03 (-1.47%)

UNIT

Uniti Group

$17.47

-0.93 (-5.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

MIK

Michaels

$21.13

-0.36 (-1.68%)

15:00
09/19/17
09/19
15:00
09/19/17
15:00
Options
Call buyers in Michaels Companies »

Call buyers in Michaels…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$2.01

-0.03 (-1.47%)

14:59
09/19/17
09/19
14:59
09/19/17
14:59
Hot Stocks
S&P downgrades Windstream to 'B' with negative outlook »

S&P Global Ratings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RDNT

RadNet

$11.10

-0.05 (-0.45%)

14:59
09/19/17
09/19
14:59
09/19/17
14:59
Hot Stocks
RadNet VP Linden sells 18,000 shares of company stock »

RadNet VP Jeffrey Linden…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

14:51
09/19/17
09/19
14:51
09/19/17
14:51
General news
Mexico Bolsa market halts trading following earthquake, Bloomberg reports »

Equities, fixed income,…

FDX

FedEx

$215.92

0.84 (0.39%)

14:49
09/19/17
09/19
14:49
09/19/17
14:49
Options
Fedex options imply 4.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

14:47
09/19/17
09/19
14:47
09/19/17
14:47
Technical Analysis
Technical View: Ubiquiti heading down in late afternoon trading »

The shares have been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Nov

VLO

Valero

$72.67

0.47 (0.65%)

14:44
09/19/17
09/19
14:44
09/19/17
14:44
Periodicals
Valero says responding to fire at Port Arthur refinery, Reuters reports »

Valero has confirmed that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

UBNT

Ubiquiti

$50.62

-4.335 (-7.89%)

14:42
09/19/17
09/19
14:42
09/19/17
14:42
Recommendations
Ubiquiti analyst commentary  »

Most Citron points on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 28

    Nov

REV

Revlon

$17.15

1.15 (7.19%)

14:40
09/19/17
09/19
14:40
09/19/17
14:40
Hot Stocks
Revlon jumps after majority shareholder Perelman says won't take private »

Shares of personal care…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLNG

Golar LNG

$21.04

-0.41 (-1.91%)

14:35
09/19/17
09/19
14:35
09/19/17
14:35
Options
Golar LNG put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWW

iShares MSCI Mexico

$55.84

-0.07 (-0.13%)

14:31
09/19/17
09/19
14:31
09/19/17
14:31
Hot Stocks
Breaking Hot Stocks news story on iShares MSCI Mexico »

iShares MSCI Mexico dips…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ICON

Iconix Brand

$5.88

0.19 (3.34%)

14:29
09/19/17
09/19
14:29
09/19/17
14:29
Initiation
Iconix Brand initiated  »

Iconix Brand initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

14:26
09/19/17
09/19
14:26
09/19/17
14:26
General news
Puebla, Mexico hit by 7.1 magnitude earthquake »

Reported by…

$NSD

NASDAQ Market Internals

14:17
09/19/17
09/19
14:17
09/19/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAIC

SAIC

$64.20

0.92 (1.45%)

14:16
09/19/17
09/19
14:16
09/19/17
14:16
Hot Stocks
SAIC moving into initial production phase for Marines' AAV SU program »

The U.S. Marine Corps…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
09/19/17
09/19
14:16
09/19/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$17.47

-0.93 (-5.05%)

14:15
09/19/17
09/19
14:15
09/19/17
14:15
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

POR

Portland General Electric

$46.57

0.21 (0.45%)

14:15
09/19/17
09/19
14:15
09/19/17
14:15
Recommendations
Portland General Electric analyst commentary  »

Portland General Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOLVY

Volvo

14:01
09/19/17
09/19
14:01
09/19/17
14:01
Periodicals
Volvo to expand South Carolina production plant, CNBC reports »

Volvo is adding an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PETS

PetMed Express

$35.81

0.25 (0.70%)

13:55
09/19/17
09/19
13:55
09/19/17
13:55
Hot Stocks
PetMed lower after unverified Twitter user mentions SEC investigation »

Unverified Twitter user…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$53.68

-3.6695 (-6.40%)

13:55
09/19/17
09/19
13:55
09/19/17
13:55
Conference/Events
Best Buy to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 22

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.